Cumulative burden of depression and domain-specific cognitive impairment over time in the women’s interagency HIV study: A marginal structural model approach

By afschroeder • November 13, 2025

Tejera CH, Duggal P, Diaz M, Topper E, Gustafson D, Jamieson BD, Maki PM, Sharma A, Spence AB, Weber KM, Weinstein AM, Jones DL, Fazeli PL, Wingood G, Teplin L, Rubin LH, Fitzgerald KC. Cumulative burden of depression and domain-specific cognitive impairment over time in the women's interagency HIV study: A marginal structural model approach. J Affect Disord. 2026 Jan 15;393(Pt B):120382. doi: 10.1016/j.jad.2025.120382. Epub 2025 Oct 9. PMID: 41076158.

Tags: cognitive impairment, Cohort study, depressive symptoms, Hematology/Oncology, HIV, Publications

Related Posts

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram[...]

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]